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We thank Tran et al. (1) for their appreciation of our open innovation platform (https://opnme.com/) and interest in our manuscript (2) in which we demonstrate that the small-molecule KRAS inhibitor BI-2852 reduces pERK (EC 50 = 6 μM) and inhibits proliferation (EC 50 = 7 μM) in NCI-H358 cells. Tran et al. (1) propose that BI-2852 exerts its cellular effects on the MAPK pathway at least in part through stabilization of a nonfunctional KRAS dimer. No cellular data for KRAS dimer induction are provided and the hypothesis is primarily based on KRAS dimer formation observed with size exclusion chromatography using concentrations 1,000 times higher (3 mM) than those in which the cellular effects of BI-2852 are observed. Hence, inhibiting the protein-protein interactions between KRAS and its GEFs, GAPs, and downstream effectors is a more plausible explanation than induction of inactive KRAS dimers for the cellular mode of action for BI-2852 (2).
However, we concur that stabilization of nonfunctional KRAS dimers as a potential therapeutic approach to treat KRAS-driven cancers is intriguing. Accordingly, we have synthesized a range of dimeric switch I/II pocket binders in analogy to linkerology (3) in the PROTAC field. We discovered compound 2, which dimerizes KRAS with a K D of 3.8 μM according to isothermal calorimetry measurements ( Fig. 1E ). Using our highthroughput crystal-soaking system for active KRAS G12D (4) (Fig. 1C ), we obtained a dimeric KRAS structure with 2 ( Fig. 1D ) at a resolution of 1.9 Å (Fig. 1G ), which represents the inactivating effector lobe dimer form 1 identified by Jang et al. (5) using molecular dynamics calculations. Cocrystallization of 2 with GCP-KRAS G12D leads to the same KRAS dimer as observed for BI-2852 ( Fig. 1 A and B) , which is the second effector lobe form proposed by Jang et al. (5) at a resolution of 1.57 Å (Fig.  1F ). In order to investigate the potential of smallmolecule stabilization of nonfunctional KRAS dimers for the treatment of KRAS-driven cancers, more permeable and potent compounds will be needed to enable cellular studies. 
